Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
ID: 341325Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/341325

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAS-22-197.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" through its Small Business Technology Transfer Research (STTR) program. This initiative aims to support small businesses in the U.S. that are focused on developing innovative therapies, products, and healthcare solutions to prevent and treat Alzheimer's disease and related dementias. The funding is critical for advancing research in areas such as prevention, diagnosis, treatment, and caregiving technologies, with a total anticipated funding amount of approximately $4 million for fiscal year 2023, expected to support around 10 awards. Interested applicants must submit their proposals by September 5, 2025, and can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAS-22-197.html
    The Department of Health and Human Services is offering a funding opportunity titled "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" through the National Institute on Aging and the National Institute of Neurological Disorders and Stroke. The initiative is aimed at supporting the development of innovative therapies, products, and healthcare solutions for AD and ADRD. Eligible applicants include small businesses in the U.S. focused on research, with grants available in various phases (Phase I, II, and Fast-Track). The total funding amount anticipated for fiscal year 2023 is around $4 million for an estimated 10 awards. The funds can cover direct costs up to $500,000 for Phase I and $2.5 million for Phase II applications. Applications must focus on various themes such as prevention, diagnosis, treatment, and caregiving technologies for individuals with AD/ADRD. Key review criteria include the proposal's significance, innovation, approach, and impact on clinical or scientific advancement. Overall, this funding opportunity emphasizes collaborative, transformative research and aims to reduce the burden of Alzheimer's disease through innovative solutions in the healthcare sector while encouraging small business participation.
    Similar Opportunities
    Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting early- and late-stage clinical trials focused on Alzheimer's Disease (AD), Alzheimer's Disease-Related Dementias (ADRD), and age-related cognitive decline. This initiative seeks applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive, behavioral, and neuropsychiatric changes associated with these conditions, as well as studies to enhance trial design and methodologies. The funding opportunity, categorized under health-related discretionary grants, is intended for small businesses with expertise in aging research, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 5, 2025. For further inquiries, interested applicants can contact Laurie Ryan, Ph.D., at 301-496-9350 or via email at ryanl@mail.nih.gov.
    Dementia Care and Caregiver Support Intervention Research - Stage I Only
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity titled "Dementia Care and Caregiver Support Intervention Research - Stage I Only," aimed at supporting research focused on developing behavioral interventions for individuals living with Alzheimer's disease and related dementias, as well as their caregivers. This initiative will utilize the R34 activity code and is designed to facilitate the development, modification, and refinement of principle-based behavioral interventions, ensuring their acceptability and feasibility in preparation for later-stage clinical trials. Interested small businesses are encouraged to begin forming collaborations and developing project proposals, with the estimated synopsis posting date on November 1, 2025, and a closing date for applications expected by February 16, 2026. For further inquiries, potential applicants can contact Melissa Riddle, Ph.D., at melissa-riddle@nih.gov or by phone at 301-480-6761.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    National Alzheimer’s Coordinating Center (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the establishment of a National Alzheimer's Coordinating Center (NACC) under a cooperative agreement. The NACC aims to serve as a national data resource for Alzheimer's disease and related dementias (AD/ADRD) research, facilitating data collection from Alzheimer’s Disease Research Centers (ADRCs) and enhancing communication within the ADRC program. This initiative is crucial for advancing research in the field of aging and dementia, providing a centralized hub for collaboration and data sharing. Interested small businesses are encouraged to prepare for the application process, with the estimated synopsis posting date on August 15, 2025, and the anticipated award date set for July 15, 2026. For further inquiries, potential applicants can contact Dr. Cerise Elliott at elliottce@nih.gov or by phone at 301-496-9350.
    Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the Alzheimer's Clinical Trials Consortium (ACTC) aimed at developing and implementing multi-site Phase Ib to III clinical trials for interventions targeting Alzheimer's disease (AD) and related dementias (ADRD). This initiative seeks to foster collaborative efforts between applicants, the National Institute on Aging (NIA), and the ACTC network to test promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat symptoms associated with AD and ADRD. The funding opportunity, utilizing the R01 activity code, is particularly significant as it addresses the growing need for effective treatments for age-related cognitive decline. Interested small businesses are encouraged to prepare for application submission, with the estimated synopsis post date on August 1, 2025, and a closing date of October 5, 2025. For further inquiries, potential applicants can contact Laurie Ryan, Ph.D., at 301-496-9350 or via email at ryanl@mail.nih.gov.
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative aims to streamline the early-stage evaluation of promising pharmacological interventions by bundling independent protocols for phase 1 clinical trials with phase 1b/phase 2a trials, focusing on non-amyloid/non-tau mechanisms that address cognitive and neuropsychiatric symptoms across various stages of the disease. The program is particularly significant given the rising prevalence of Alzheimer's and the associated economic burden, emphasizing the need for innovative treatments as the aging population grows. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with proposals due by November 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD) through the R01 Clinical Trial Optional grant program. This initiative aims to support innovative research that addresses significant biomedical, social, and behavioral aspects of aging, with a focus on inclusivity and diversity in participant recruitment. Given the projected rise in expenditures for AD-related care, which could exceed $1 trillion by 2050, this funding is critical for advancing understanding and treatment of dementia-related challenges. Interested applicants can find more information and submission guidelines at the NIH grants website, with applications due by November 5, 2027, and no specific budget limits outlined.
    Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing drug repositioning and combination therapy development for Alzheimer's Disease (AD) and related dementias (ADRD). This initiative invites applications that utilize mouse models to conduct rigorous preclinical testing of FDA-approved drugs or investigational compounds, with the goal of establishing proof of concept for effective treatment strategies. Given the historical challenges in developing successful AD therapies, this program emphasizes a systematic approach and encourages collaboration between academia and industry to enhance research rigor and reproducibility. Applicants may receive up to $1 million annually, with a total funding pool of $6 million available for 4-5 awards. The application deadline is May 7, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Seamless Early-Stage Clinical Drug Development program, aimed at accelerating the clinical evaluation of novel treatments for Alzheimer’s Disease (AD) and related dementias (ADRD). This funding opportunity utilizes the UG3/UH3 phased award mechanism to streamline the assessment of pharmacological interventions that engage non-amyloid/non-tau mechanisms, requiring applicants to bundle independent protocols for Phase 1 and Phase 1b/Phase 2a clinical trials while achieving specified safety and tolerability milestones. This initiative is critical in addressing the growing human and economic burdens posed by AD and ADRD, reflecting a commitment to innovative treatment development. Interested applicants must adhere to submission guidelines, with the earliest application deadline set for January 19, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.